

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

ERC1671 for treating progressed or recurrent glioblastoma [ID1623]

Final stakeholder list of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • Epitopoietic Research Corporation (ERC1671) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Astro Brain Tumour Fund • Black Health Agency • Brain and Spine Foundation • Brain Tumour Action • Brain Tumour Charity • Brainstrust • Cancer 52 • Cancer Black Care • Cancer Equality • Headcase Cancer Trust • Helen Rollason Cancer Charity • Independent Cancer Patients Voice • Macmillan Cancer Support • Maggie's Centres • Marie Curie • Muslim Council of Britain • Neurological Alliance • South Asian Health Foundation • Specialised Healthcare Alliance • Tenovus Cancer Care • Tony Souster Glioblastoma Charity <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of British Neurologists • Association of Cancer Physicians • Association of Surgeons of Great Britain and Ireland • British Association of Head and Neck Oncologists • British Association of Head and Neck Oncology Nurses • British Association of Surgical 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics & Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare Products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Welsh Health Specialised Services Committee <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • Accord Healthcare (temozolomide) • Alliance Pharmaceuticals (procarbazine) • Eisai (carmustine implants) • Hospira UK (vincristine sulfate) • Medac UK (lomustine) • Merck Sharp & Dohme (temozolomide) • Pfizer (vincristine sulfate) • Sun Pharmaceutical Industries Europe (temozolomide) • Teva UK (vincristine sulfate) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Andrew McCartney Trust Fund for Brain Tumour Research • Brain Tumour Research

Final stakeholder list for the technology appraisal of ERC1671 for treating progressed or recurrent glioblastoma ID1623 Issue date: November 2019

Consultees	Commentators (no right to submit or appeal)
<p>Oncology</p> <ul style="list-style-type: none"> • British Geriatrics Society • British Institute of Radiology • British Psychosocial Oncology Society • British Skull Base Society • Cancer Research UK • Royal College of Anaesthetists • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal College of Radiologists • Royal College of Surgeons • Royal Pharmaceutical Society • Royal Society of Medicine • Society and College of Radiographers • Society of British Neurological Surgeons • UK Clinical Pharmacy Association • UK Health Forum • UK Oncology Nursing Society <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS England • NHS Newcastle Gateshead CCG • NHS Sutton CCG • Welsh Government 	<ul style="list-style-type: none"> • Brain Tumour Research Campaign • Genomics England • Institute of Cancer Research • Institute of Neurology, UCL • MRC Clinical Trials Unit • National Cancer Research Institute • National Cancer Research Network • National Institute for Health Research • Oracle Cancer Trust <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical specialists or patient experts.

¹ Non-company consultees are invited to submit statements relevant to the group they are representing.